A new blood test test could determine how far Alzheimer's has progressed and could also help confirm whether another ...

Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical ...

A potential new biomarker for predicting future cognitive resilience versus decline among people with early Alzheimer's ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

people’s brain function is already declining. The scans are also expensive and not available at all hospitals. More sensitive ways to detect amyloid and tau, another protein related to the ...

Worley was part of a team that showed how the loss of one of the two proteins used in the test disrupts synapses and leads to ...

Those findings were integrated with data collected from the participants on cerebrospinal fluid and brain-scan biomarkers of amyloid- β and tau protein, cognitive function, age, sex and Alzheimer ...